Consensus statement: New Zealand guidelines for the detection and management of nephropathy in diabetes

New Zealand Medical Journal

Volumn 109, Issue 1031, 1996, Pages 378-381

  Drury, Paul ^a  

^a Auckland Diabetes Centre   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; HYDRALAZINE;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; HUMAN; KIDNEY FUNCTION; MICROALBUMINURIA; PRACTICE GUIDELINE; PROTEINURIA; SHORT SURVEY;

ALGORITHMS; DECISION TREES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MASS SCREENING; NEW ZEALAND; SOCIETIES, MEDICAL;

EID: 16044363633     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. Mogensen CE, Ritz E, eds. Symposium: Diabetic renal disease in type 2 diabetic patients. A major worldwide health problem. Diabetologia 1993; 36: 977-1117.
2. Disney APS, ed. 18th report of the Australia and New Zealand dialysis and transplant registry. Australian Kidney Foundation, 1995.
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
4. Bojestig M, Arnqvist HJ, Hermansson G, et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15-8
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
6. Viberti GC, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271: 275-9.
7. Kasiske BL, Kalil RSN, Ma JZ, et al. Effect of hypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-38.
8. Ravid M, Savin H, Jutrin I, et al. Long-term stabilising effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-8.
9. Borch-Jensen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin-dependent diabetes? BMJ 1993; 306: 1722-5.
10. Gilbert RE, Cooper ME, McNally PG, et al. Microalbuminuria: prognostic and therapeutic implications in diabetes mellitus. Diabetic Med 1994; 11: 636-45.
11. Jerums G, Cooper M, Gilbert R, O'Brien R, Taft J. Microalbuminuria in diabetes. Med J Aust 1994; 161: 265-8.
12. American Diabetes Association. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994; 17: 1357-61.
13. Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. Diab Care 1995: 18: 572-81.
14. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-4.
15. Alzaid AA. Microalbuminuria in patients with NIDDM: an overview. Diabetes Care 1996; 19: 79-89.
16. Cundy TF, Nixon D, Berkahn L, Baker J. Measuring the albumin excretion rate: agreement between methods and biological variability. Diabetic Med 1992; 9: 138-143.
17. Dyslipidaemia Advisory Group. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996; 109: 224-32.